Comparison of R-miniCHOP with R-Bendamustine (R-B) in diffuse large B-cell Lymphoma (DLBCL) in elderly and comorbid patients

被引：0
|
作者：
Hammersen, F. J. [1 ]
Ruethrich, M. M. [1 ]
Wedding, U. [2 ]
Sommer, M. [3 ]
Hochhaus, A. [1 ]
La Rosee, P. [4 ]
机构：
[1] Univ Klinikum Jena, Hamatol internist Onkol, Klin Innere Med 2, Jena, Germany
[2] Univ Klinikum Jena, Palliat Med, Klin Innere Med 2, Jena, Germany
[3] Inst Allgemeinmed Jena, Jena, Germany
[4] Schwarzwald Baar Klinikum Villingen Schwenningen, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P173
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [31] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Hui, D.
    Proctor, B.
    Donaldson, J.
    Shenkier, T.
    Hoskins, P.
    Klasa, R.
    Savage, K.
    Gascoyne, R.
    Connors, J. M.
    Sehn, L. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 186 - 187
  • [32] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Proctor, B. R.
    Hui, D.
    Donaldson, J.
    Savage, K. J.
    Shenkier, T. N.
    Hoskins, P. J.
    Klasa, R.
    Randy, G.
    Joseph, C.
    Sehn, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A single institution analysis of R-CHOP-14 vs.-21 in diffuse large B-cell lymphoma (DLBCL) in elderly patients
    Ruethrich, M. M.
    Hammersen, F. J.
    Hochhaus, A.
    La Rosee, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 36
  • [34] Diffuse large B-cell lymphoma (DLBCL)
    Renner, C.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S10 - S10
  • [35] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [36] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Yung, Mallory
    Schnell, Frederick
    Vukcevic, Mirko
    Kurukulasuriya, Nuwan C.
    BLOOD, 2021, 138 : 1928 - +
  • [37] Diffuse large B-cell lymphoma: R-CHOP forever?
    Jedrzejczak, Wieslaw W.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (10): : 713 - 714
  • [38] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [39] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Herrera, Alex F.
    Matasar, Matthew J.
    Assouline, Sarit
    Kamdar, Manali
    Mehta, Amitkumar
    Fleury, Isabelle
    Kim, Won Seog
    Kim, Tae Min
    Bosch, Francesc
    Radford, John A.
    Bu, Lilian
    Hong, Wan-Jen
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [40] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
12345